Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. L-Lysine increased the cytotoxicity effect of doxorubicin in MDA-MB-231 and MDA-MB-468 breast cancer cell lines

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

  2. TSGA10 and H2AX competition over binding HIF-1 in breast cancer

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. Human endogenous retroviruses and their implication for immunotherapeutics of cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A small change makes a big difference in Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Improvements in Imaging of Hodgkin Lymphoma: Positron Emission Tomography

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral T-cell lymphoma patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • A Younes
  • P Hilden
  • B Coiffier
  • A Hagenbeek
  • G Salles
  • W Wilson
  • J F Seymour
  • K Kelly
  • J Gribben
  • M Pfreunschuh
  • F Morschhauser
  • H Schoder
  • A D Zelenetz
  • J Rademaker
  • R Advani
  • N Valente
  • C Fortpied
  • T E Witzig
  • L H Sehn
  • A Engert
  • R I Fisher
  • P-L Zinzani
  • M Federico
  • M Hutchings
  • C Bollard
  • M Trneny
  • Y A Elsayed
  • K Tobinai
  • J S Abramson
  • N Fowler
  • A Goy
  • M Smith
  • S Ansell
  • J Kuruvilla
  • M Dreyling
  • C Thieblemont
  • R F Little
  • I Aurer
  • M H J Van Oers
  • K Takeshita
  • A Gopal
  • S Rule
  • S de Vos
  • I Kloos
  • M S Kaminski
  • M Meignan
  • L H Schwartz
  • J P Leonard
  • S J Schuster
  • V E Seshan
Vis graf over relationer

In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.

OriginalsprogEngelsk
TidsskriftAnnals of Oncology
Vol/bind28
Udgave nummer7
Sider (fra-til)1436-1447
Antal sider12
ISSN0923-7534
DOI
StatusUdgivet - 1 jul. 2017

ID: 52764973